Biopharma and life sciences companies bolster their executive leadership teams and boards with these Movers & Shakers.

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

Crysvita is a drug developed by Ultragenyx Pharmaceutical and Tokyo-based Kyowa Kirin Co. Ltd., a specialty pharmaceutical company.

The company indicated the initial data was promising, but the data for overall survival benefit and additional secondary endpoints were not yet mature and the trial will continue.

According to a BioPharma Dive report, since March, more than 100 biopharma companies announced their clinical trials were disrupted in some way because of the pandemic.

Mayo Clinic researchers and collaborators have found investigational convalescent plasma to be safe following transfusion in a diverse group of 20,000 patients. The findings - from the U.S. Food and Drug Administration's Expanded Access Program for COVID-19 - are reported in Mayo Clinic Proceedings.

Researchers at the University of Maryland School of Medicine (UMSOM) evaluated several human antibodies to determine the most potent combination to be mixed in a cocktail and used as a promising anti-viral therapy against the virus that causes COVID-19. Their research, conducted in collaboration with scientists at Regeneron Pharmaceuticals, was published in the journal Science.

The company announced it planned to soon start enrolling an open-label, single-arm Phase II/III clinical trial of remdesivir in about 50 pediatric patients with moderate-to-severe COVID-19, including newborns through adolescents.

In a Phase III study, Genentech’s Tecentriq (atezolizumab) in combination with Celgene’s Abraxane followed by chemotherapy demonstrated a statistically significant and clinically meaningful improvement in treating patients with early triple-negative breast cancer.

Pfizer and Sangamo Therapeutics released follow-up data from its Phase I/II Alta study in hemophilia A that showed an investigational gene therapy treatment provided blood-clotting activity levels for more than one year.

Biopharma and life sciences companies from across the globe provide updates on their pipelines and business operations.

Vikram Sudarsan, president and chief executive officer of Engrail, said the latest strides made in the field of neuroscience have buoyed the hopes of investors such as NFLS in funding drug development in this area.

New research out of the Memorial Sloan Kettering Cancer Center suggests the genetically engineered immune cells can be used to treat diseases of senescence, which could include fibrotic liver disease, atherosclerosis, and diabetes.

Under the terms of the deal, AbbVie is paying Alpine an upfront payment of $60 million for rights to ALPN-101, a first-in-class dual CD28/ICOS costimulation antagonist.

A new study published on Wednesday in the journal Nano Letters showed that cellular nanosponges may be able to inhibit SARS-CoV-2 infectivity within the body, ultimately neutralizing the virus.

The session discussed three “out-of-the-box” innovations that apply to multiple types of addictions.

Specifically, the product was examined for its use in subjects where pituitary surgery is not an option or has not be curative.

The U.S. Court of Appeals upheld a ruling that the Trump administration does not have the legal authority to mandate that drug companies disclose the list price of medications in television advertisements.

We’re all called on at some point to give feedback to our bosses or employees, colleagues or direct reports, regardless of whether or not you hold a leadership position. And often that feedback is given in response to a negative situation or action that has taken place and needs to be addressed.

Sanofi detailed plans on how the Company will make significant investments in France to increase its vaccines research and production capacities, and contribute in responding to future pandemic risks. Aligned with its corporate strategy presented last December, Sanofi will invest €610 million to create a new production site and research center in France with both dedicated to vaccines.